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ABSTRACT
Neuropathic pain is a frequent and disabling
condition with diverse underlying etiologies
and is often difficult to treat. Systemic drug
treatment is often limited in efficacy.
Furthermore, adverse effects may be a limiting
factor when trying to reach the necessary dose.
Analgesics that can be applied topically have
the potential to largely overcome this problem.
They may be of particular advantage in
localized neuropathic pain syndromes such as
postherpetic neuralgia or small fiber
neuropathy. Capsaicin, the pungent
component of chili peppers, is a natural ligand
of the transient receptor potential vanilloid 1
channel and has long been used as topically
applicable cream with concentrations of 0.025
to 0.075%. In 2009, a high-concentration
transdermal capsaicin 8% patch (Qutenza;
Acorda Therapeutics, Inc., Ardsley, NY, USA;
Astellas Pharma Europe Ltd., Chertsey, Surrey,
UK) was introduced for the treatment of
peripheral neuropathic pain syndromes other
than of diabetic origin in adults. It has since
been widely used in diverse neuropathic pain
disorders. In this review article, we summarize
current knowledge on Qutenza, its advantages
and problems, and expose unmet needs.
Keywords: Analgesia; Capsaicin; Neuropathic
pain; Qutenza; Transient receptor potential
vanilloid 1 (TRPV1)
NEUROPATHIC PAIN
Neuropathic pain is caused by a lesion or disease
of the somatosensory nervous system [1] and
affects an estimated 8% of the general
population [2], leading to severe impairment
and reduction of health-related quality of life.
The peripheral nervous system is more
frequently the source of neuropathic pain
rather than the central nervous system.
Examples for peripheral neuropathic pain
syndromes include postherpetic neuralgia
(PHN), painful diabetic neuropathy, human
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immunodeficiency virus (HIV)-associated
neuropathy, or chemotherapy-induced
neuropathic pain. Phantom limb pain after
amputation is considered to have a peripheral
and central component. Spinal cord injury pain
or pain due to cerebral infarction would be
examples for centrally induced neuropathic
pain conditions. Peripheral neuropathic pain is
mostly localized in the area supplied by the
affected nerves and is reported to be of burning,
stabbing, or electrifying character. Additional
symptoms are plus symptoms such as
hyperalgesia (i.e., increased pain upon
application of painful stimulus), allodynia (i.e.,
pain upon application of painless stimulus),
painless paresthesias, or painful dysesthesias,
and minus symptoms that include hypoesthesia
and hypoalgesia [3]. While neuropathic pain
and additional symptoms initially may be of
episodic character, in the majority of cases pain
becomes permanent and chronic in the long
term.
The causes of neuropathic pain are diverse.
From the clinical point of view, trauma,
hemorrhage, ischemia, inflammation, or
metabolic alterations are some examples of
how the central and the peripheral parts of the
somatosensory nervous system can be impaired.
However, this small and selective list of
possibilities already implies that the
pathophysiological mechanisms underlying
neuropathic pain are manyfold. These
mechanisms are still incompletely understood
despite intensive research.
Pathological ion channel activity is of
particular importance when discussing
neuropathic pain pathophysiology. Different
subgroups of ion channels are critically
involved in neuropathic pain development via
ectopic discharges and sensitization. The family
of voltage-gated sodium channels (NaV) is an
outstanding example since the discovery of
mutations in the gene of Nav1.7 as the
molecular basis of erythromelalgia first opened
the avenue of genetic pain research [4]. Another
family of voltage-gated ion channels that has a
crucial role in neuropathic pain is the transient
receptor potential (TRP) family. The TRP
channels regulate action potential firing
frequencies by gating neuronal transmembrane
ion influx and modulate the sensitivity of
afferent somatosensory neurons [5]. Another
factor inducing and maintaining neuropathic
pain is the dysfunctional effect and imbalance of
algesic and analgesic mediators like cytokines or
chemokines during neuro-immune interactions
in the peripheral and central nervous system [6].
NaV as well as TRP channels are modulated by
these mediators [7, 8].
So far, the best studied member of the TRP is
the transient receptor potential vanilloid 1
(TRPV1) channel [9]. This non-selective cation
channel is highly expressed on thinly
myelinated A-delta fibers and unmyelinated C
fibers (nociceptors) and is in particular
permeable to calcium ions. TRPV1 activation
typically leads to burning pain sensation and
heat hyperalgesia [9]. Numerous TRPV1
activators are known to date that include high
temperatures ([42 C), acidic pH, and the
pungent ingredient of hot chili peppers,
capsaicin, which is a natural ligand of TRPV1
and makes this channel a delicate candidate for
pain research.
CURRENT PHARMACOLOGICAL
TREATMENTS OF NEUROPATHIC
PAIN AND UNMET NEEDS
Treatment of neuropathic pain follows national
[10, 11] and international guidelines [12, 13]
that broadly overlap with regard to
recommendations. In most guidelines, first-
line therapy is the use of oral drugs such as
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tricyclic antidepressants (e.g., amitriptyline),
anticonvulsants including calcium channel
blockers (e.g., gabapentin, pregabalin), and
selective serotonin and noradrenalin reuptake
inhibitors (e.g., duloxetine). In the case of
localized pain, topical lidocaine can be applied
as well as capsaicin cream or patch. If patients
do not respond or have mixed pain (i.e.,
neuropathic pain plus nociceptive pain) the
use of opioids can be considered [10].
Oral medication is used by the majority of
patients suffering from neuropathic pain;
however, only one-third of these patients seem
to achieve satisfying pain relief [14]. Thus, the
main problem with oral drugs is the lack of
efficacy in a large proportion of patients even
after intake of a sufficient dosage, changing to
alternative drugs, and when used in
combination. In addition, the occurrence of
systemic side effects such as weight gain,
xerostomia, dizziness, nausea, or cognitive
impairment hampers acceptance. The fact that
oral medication also needs individual titration
and regular intake on a daily basis is an
additional limitation reducing flexibility in
life, especially for young patients. Drug–drug
interactions may also constrain the already
limited treatment options, especially in elderly
patients with comorbidities. In this context,
drug dosage needs to be adapted if renal or
hepatic impairment is present. The effect of oral
analgesic drugs also starts late; for some drugs
an intake period of 6–8 weeks at the maximum
dose is needed before drug efficacy can be
judged. In localized neuropathic pain states,
topically applicable lidocaine and ketamine, as
well as low-dose capsaicin cream
(0.025–0.075%), are in use. However, these
require regular administration and also bear
less hazardous but inconvenient disadvantages
(e.g., potential contamination of hands during
application or clothes afterwards).
Thus, despite a major effort to improve and
facilitate oral analgesics there are still several
challenges to be taken to meet the needs of
patients with neuropathic pain syndromes [15].
One key obstacle is the lack of knowledge on
the precise mechanisms that underlie the
different types of neuropathic pain and that
drugs are chosen mostly with regard to
neuropathic pain in general without
differentiation. Neuropathic pain, in general,
covers many diverse entities that are of such a
different pathophysiological background that a
‘‘one-drug-good-for-all’’ approach is condemned
to failure. A second problem is that currently
available analgesic pharmaceuticals are not
exclusively selective for one target. Unselective
drug choice (i.e., treating neuropathic pain in
general) and molecularly relative unselective
drugs (i.e., binding to different targets) are the
major reasons that lower drug efficacy and
tolerability. Therefore, the transdermal
capsaicin 8% patch Qutenza (Acorda
Therapeutics, Inc., Ardsley, NY, USA; Astellas
Pharma Europe Ltd., Chertsey, Surrey, UK) has
been an important addition to the treatment
options in neuropathic pain conditions [16].
HIGH-DOSE CAPSAICIN
Mechanism of Action
Transient receptor potential vanilloid 1 is
selectively expressed in nociceptors. The distal
endings of cutaneous nociceptors are present in
the epidermis and are thus accessible to local
treatment. The high-concentration transdermal
8% capsaicin patch Qutenza releases capsaicin
into the skin, which can then act on TRPV1
receptors on the nociceptor terminals. This
leads to an initial over-excitation of these
nerve fibers, which is perceived as burning
pain by patients. After this initial excitation,
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the axons are believed to be ‘‘defunctionalized’’,
that is, to be less sensitive to external stimuli
and also to cease any spontaneous activity that
may have been present. Morphologically,
intraepidermal nerve fiber endings disappear
after capsaicin application, which can be
assessed using immunohistochemistry and the
panaxonal marker protein gene product (PGP)
9.5 which is routinely used to visualize
intraepidermal nerve fibers [17]. In the case of
Qutenza, these nerve fiber endings recover after
24 weeks, at least in healthy volunteers [18].
Investigations in patients with pain states
treated with capsaicin have not been
performed so far. Thus, several questions
remain, such as a potential correlation
between fiber density and pain intensity and
the phenotype of the regenerating fibers with
regard to their channel repertoire. Also,
whether this disappearance and recovery of
immunostaining for PGP 9.5 reflects true
degeneration and regeneration or repressed
production of the antigen detected in the
immunofluorescence, is as yet unknown.
Another potential mechanism is based on the
interaction of TRPV1 with b-tubulin. TRPV1
activation leads to a microtubule disassembly
in vitro by direct action and supported by the
axonal calcium ion overload via excessive ion
influx [19]. Whether Qutenza has a similar
effect in vivo remains to be proven.
One apparent paradox is that neuropathic
pain states are usually associated with a loss of
intraepidermal nociceptor terminals [20, 21]. If
these target fibers are gone, where would a
TRPV1 agonist bind? The most favored
hypothesis in this context is that the
remaining nociceptors become hyperactive
and hypersensitive on the basis of alterations
in TRPV1 channel activity and expression.
There is evidence for an increase in TRPV1
channel quantity on inflamed nociceptors [22]
and also for the sensitization of these
nociceptors by local algesic inflammatory
mediators and growth factors [23, 24].
There are several other unsolved questions. It
is unclear why some patients do respond to
Qutenza treatment and others do not. If
Qutenza leads to nociceptor
defunctionalization or degeneration, then all
patients suffering from peripheral neuropathic
pain should experience pain relief. Here,
diversity of neuropathic pain pathophysiology
and mechanisms is important. Obviously,
TRPV1-mediated pain is not responsible for all
neuropathic pain states. This is also
underscored by the fact that some patients
develop a skin flush upon patch application
which can be associated with severe additional
burning patch-pain for days to weeks and some
do not. Interestingly, the development of such a
patch-pain does not predict treatment response
[41]. No data are available about how deep
capsaicin from the Qutenza patch penetrates
the different skin layers and how much
capsaicin reaches the nociceptors. Skin
penetration studies with Qutenza are ongoing,
as with other novel formulations [25]. It is also
not known whether capsaicin acts on peripheral
nerve TRPV1 channels only or if an action, for
example, on keratinocyte TRPV1 channels, also
plays at least a modulatory role [26]. The
pharmacokinetics of capsaicin in the skin are
still under investigation (J. Wohlrab, personal
communication, January 2014).
Dose and Administration, and Benefits
of Localized Rather Than Systemic
Analgesia
The application of the transdermal capsaicin 8%
patch Qutenza containing 179 mg capsaicin
needs to be performed at a medical center as
special precautions are needed [27]. First, the
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area that needs to be treated has to be
determined and marked by the treating
physician or the applying nurse. Afterwards,
the skin is cleaned and lidocaine gel may be
applied to reduce patch-induced pain;
alternatively, patients may take oral analgesics
(e.g., tramadol) prior to Qutenza application
(see below). Thereafter, the Qutenza patch is
placed on the affected region for 30 min if the
feet are treated or for 60 min for any of the
other approved body regions. After this time,
the patch is removed and the affected skin area
is cleansed. The effect of the Qutenza patch
starts within days and analgesia can be achieved
for at least 12 weeks. After this time treatment
can be repeated.
The major advantages of the localized
treatment are that potential systemic side
effects of Qutenza, comprising hypertension,
first-degree atrioventricular block, coughing, or
nausea, occur very rarely. Side effects that are
usually associated with the intake of analgesics
like cognitive impairment or drowsiness are
absent. This is of particular relevance for young
patients who work and drive cars. For elderly
patients who also need to take other drugs, the
local application of transdermal Qutenza is an
advantage since no drug–drug interactions will
occur.
Clinical Trial Data That Led to its Launch,
Including the Recent EC Approval
for Expanded Treatment Options
In 2009, the European Medicines Agency
approved the use of Qutenza for the treatment
of peripheral neuropathic pain other than of
diabetic origin in adults as a monotherapy or in
combination with other analgesic drugs [28].
The approval was based on data from
randomized, double-blind, placebo controlled
studies in patients with PHN [29–32] and
painful HIV-associated neuropathy [33, 34] on
the efficacy and safety of transdermal 8%
capsaicin versus a control patch with low-dose
capsaicin (0.04%).
In one multicenter, randomized-controlled
trial (RCT), 206 patients with PHN were treated
with transdermal 8% capsaicin and 42% of them
reported a C30% reduction in pain intensity
versus 32% in patients treated with the placebo
patch [29]. Similar results were reported by
others after application of the 8% capsaicin
patch in 194 patients [31]. In another RCT, 32
patients with PHN were randomized to be
treated with transdermal 8% capsaicin; a
decrease in pain intensity ratings of
approximately 30% in the verum group
compared to the control group was reported
[30]. The treatment of 200 patients with PHN
with 8% capsaicin patch led to a reduction of the
mean percentage of pain ratings that was greater
than in the placebo group [32]. In 225 patients
with painful HIV-associated neuropathy,
transdermal 8% capsaicin led to a reduction in
pain ratings in 23% of patients on verum versus
11% of patients on placebo [34]. In another
study this effect could not be confirmed [33].
Taken together one study [33] out of six was
negative on the primary outcome with the
capsaicin 8% patch, while in the other five
studies more patients reported a positive effect
when treated with the high-concentration patch
compared to the low concentrated patch, as also
stated in a recent Cochrane review [35]. Table 1
summarizes the major characteristics of the
reported studies [29–34].
Particularly when comparing data of the
verum (high-dose) and control (low-dose)
patch in the reported studies, it is apparent
that a low-dose capsaicin patch may also have a
notable analgesic effect. In the majority of the
studies summarized in Table 1 the difference in
analgesic efficacy between the high and the
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low-dose patch was less than 15%. Side effects
were reported inhomogenously in the
respective studies, however, while high-dose
capsaicin caused a higher percentage of
adverse events, the control patch also led to
similar results.
In 2013, an expanded pre-treatment
procedure was approved by the European
Commission based on the results of a study
investigating 122 patients who received either
the already approved topical lidocaine pre-
treatment before Qutenza application or
tramadol tablets [36]. Both pre-treatment
regimes proved to be equally effective and can
now be used in clinical practice.
HOW QUTENZA FITS
INTO TREATMENT REGIMENS
IN THE REAL WORLD
In clinical practice, patients with neuropathic
pain conditions are treated with oral
pharmacological drugs as first-line therapy as
recommended by national and international
guidelines. However, not all patients treated
with oral analgesic drugs experience pain relief
to a satisfying extent. The consequence is that
drug dosage is increased. If this measure also
fails to reduce pain, the medication is changed
to a drug from a different group, as detailed
above, or combination pharmacotherapy is
installed. During this mostly exhausting phase
of trial and error, the outcome may be biased by
decreasing patient compliance. The experience
of ineffective drugs with unpleasant adverse
effects reduces the motivation of the patient
and sometimes may also lead to catastrophizing.
The inconvenience of obligatory daily drug
intake is in particular difficult to accept for
young and active patients. In this situation,
Qutenza may be an alternative for the treating
physician and the patient. The novel application
and the fact that treatment is episodic are
attractive features that are very well accepted
by the patients. Qutenza can then be used as
monotherapy or in combination with oral
analgesic drugs that may, however, be reduced
in dosage. This is a good addition to the overall
small palette of possibilities for non-
interventional pharmaceutical analgesic
treatment in neuropathic pain conditions.
Current Experience
Several studies have been published after the
approval of Qutenza assessing the efficacy and
safety in patients with PHN and HIV-associated
painful neuropathy. A meta-analysis including
1,120 patients with PHN and 338 with HIV-
associated neuropathy favored Qutenza over
the low-dose capsaicin patch when assessing
the number of patients with 30% pain
reduction as primary outcome [37]. In these
trials, overall 44% of the PHN and 41% of the
HIV-associated neuropathy patients had a 30%
response. Complete pain relief 2–12 weeks after
treatment was reported in 11% of patients with
PHN and 7% of patients with HIV-associated
neuropathy [38]. It took a mean time of 3.4 days
for PHN patients and of 6.5 days for HIV-
neuropathy patients to respond. The mean
duration of response after the first Qutenza
treatment was 5 months [38]. In the largest
non-interventional study so far, QUEPP
(Qutenza—safety and effectiveness in
peripheral neuropathic pain), the effect of a
single Qutenza application was assessed over a
period of 3 months in 1,044 patients with
neuropathic pain other than of diabetic origin
[39]. The authors reported that 43% of patients
had 30% pain relief and 24% experienced 50%
pain relief. Also, pain intensity and the
frequency of pain attacks declined and
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additional intake of analgesic drugs was
reduced. In this study [39], pre-treatment pain
duration was negatively correlated to the
effectiveness of Qutenza; however, there have
been conflicting data depending on pain
etiology [31, 40, 41].
Another question is how to determine who
are responders and who are non-responders of
Qutenza treatment. Efforts have been made to
identify predictors of a positive Qutenza
response. A post hoc analysis of the clinical trial
data showed that efficacy of lidocaine
pretreatment and a high pretreatment pain
score variability were important predictors [42].
In a multi-center open study with multivariate
analysis, time of disease was a major predictor,
with a history of pain of less than 6 months being
a positive predictor for a response to Qutenza
[41]. In this context, effective lidocaine pre-
treatment and a higher pre-treatment pain score
variability were found as potential predictors of
good treatment response: older age and longer
duration of pre-treatment pain were predictors
for poorer outcome after Qutenza treatment [41,
42]. One critical aspect, however, is that a high
efficacy of the control patch (0.04%) was also
reported [33, 37, 42].
Qutenza is mostly well tolerated. The major
side effects are at site erythema, burning pain,
and itch upon patch application that may last
for days to weeks [35]. Currently no predictors
are known for who will develop patch-pain.
Also, no correlation exists so far with regard to
patch-pain and analgesic effect of Qutenza.
SUMMARY AND OUTLOOK
Neuropathic pain is a major challenge due to
chronification and low treatment response. The
non-interventional pharmacological treatment
options used so far are effective only in
subgroups of patients and are mostly afflicted
with intolerable side effects. Topically
applicable substances are of need, especially in
focal neuropathic pain conditions. Qutenza is
therefore a valuable addition to the palette of
analgesic options against neuropathic pain in
adults. The application is easy and mostly well
tolerated and leads to pain relief in a subset of
patients.
The aim is to further improve and facilitate
the Qutenza application so that, for example, it
might be applied by the patients themselves. A
further reduction in local side effects would be
desirable. Further studies are underway to
investigate the efficacy and safety of Qutenza
in other peripheral neuropathic pain states
including those related to diabetes. There are
no studies about pain relief by Qutenza in
children. Although no data are available on
the prevalence of neuropathic pain in children,
being able to use Qutenza in pediatric patients
with localized neuropathic pain might be a
worthwhile goal with regard to the general
reluctance to give systemic analgesics in child
pain management. Data on potential
biomarkers that can be used as potential
predictors of treatment response would be
useful for effective patient selection and to
avoid unnecessary treatment of pre-defined
non-responders. This may be achieved by
research focusing on the molecular
mechanisms of the interaction of transdermal
capsaicin with cutaneous cells and nerve fibers.
This article is based on previously conducted
studies, and does not involve any new studies of
human or animal subjects performed by any of
the authors.
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